Johnson & Johnson Family of Companies
NEWS
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Johnson & Johnson’s iconic talcum powder product has been the subject of lawsuits and a scathing report that indicated the company allegedly knew that carcinogenic asbestos was sometimes found in the product. As a result, the company has received subpoenas from the federal government.
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health, Inc., a company that developed robotic endoscopic technologies that can be used in the treatment of lung cancer.
Lawmakers continue to hear concerns over drug prices, as well as proposals to fix the issue.
On Tuesday, a U.S. Food and Drug Administration advisory panel overwhelmingly supported approval of the nasal spray treatment.
Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.
JOBS
IN THE PRESS